Items Tagged ‘Stage IV (D)/Relapsed Colon Cancer’

January 28th, 2016

Vectibix® Improves Survival in Colorectal Cancer, Demonstrates Importance of Tissue Testing

By

The addition of Vectibix® (panitumumab) to best supportive care improves survival over best standard care alone among colorectal cancer patients who have stopped responding to chemotherapy. However, the benefit is only seen with patients who have no RAS mutations, or those with only the KRAS exon 2 mutation. These results were recently presented at the […]

View full entry

Tags: Adjuvant (I-III, A-C) Colon Cancer, Colon Cancer, colorectal cancer, KRAS exon 2, News, panitumumab, Rectal Cancer, Recurrent/Relapsed Rectal Cancer, Stage IV (D)/Relapsed Colon Cancer, Stage IV Rectal Cancer, Stages I-III Rectal Cancer, vectibix


September 30th, 2015

Lonsurf® Approved for the Treatment of Colorectal Cancer

By

The United States Food and Drug Administration (FDA) has approved the oral agent, Lonsurf® (trifluridine and tipiracil), for the treatment of colorectal cancer. Colorectal cancer remains the second leading cause of cancer-related deaths in the U.S. although death rates from colorectal cancer have declined in the past 10 years which is thought to be due […]

View full entry

Tags: advanced, Colon Cancer, colorectal cancer, fda, Lonsurf, News, Rectal Cancer, Stage IV (D)/Relapsed Colon Cancer, Stage IV Rectal Cancer, tipiracil, trifluridine


August 24th, 2015

XBiotech Completes Enrollment for Xilonix™ Phase III Registration Study in Europe, US Trial Ongoing

By

XBiotech has announced that it has completed enrollment of the Company’s pivotal, randomized double-blinded placebo controlled Phase III study in Europe of Xilonix™ for the treatment of advanced colorectal cancer. The US based trial is ongoing at multiple sites. Xilonix, a novel anti-cancer agent, is being developed via a ground-breaking regulatory path that XBiotech established […]

View full entry

Tags: advanced colorectal cancer, clinical trail, Colon Cancer, News, Rectal Cancer, Stage IV (D)/Relapsed Colon Cancer, Stage IV Rectal Cancer, xilonix


August 11th, 2015

Vectibix® Improves Survival in Patients with Wild-Type KRAS Metastatic Colorectal Cancer after Progression on Chemotherapy

By

  Vectibix® (panitumumab) appears to improve overall survival among patients with wild-type KRAS metastatic colorectal cancer that has progressed on or following chemotherapy. A Phase III trial of Vectibix is currently underway, but researchers have announced that that drug has extended overall survival, the primary goal of the study. Vectibix is a targeted therapy that […]

View full entry

Tags: Colon Cancer, colorectal cancer, kras, metastatic colorectal cancer, News, panitumumab, Rectal Cancer, Recurrent/Relapsed Rectal Cancer, Stage IV (D)/Relapsed Colon Cancer, Stage IV Rectal Cancer, vectibix, wild-type


June 23rd, 2015

New Biomarkers Might Help Personalize Metastatic Colorectal Cancer Treatment

By

Metastatic colorectal cancer patients tend to live longer when they respond to the first line of chemotherapy their doctors recommend. To better predict how patients will respond to chemotherapy drugs before they begin treatment, researchers at University of California, San Diego School of Medicine conducted a proof-of-principle study with a small group of metastatic colorectal […]

View full entry

Tags: Colon Cancer, colorectal cancer, irinotecan, metastatic, News, oxaliplatin, Rectal Cancer, Stage IV (D)/Relapsed Colon Cancer, Stage IV Rectal Cancer


March 17th, 2015

XBiotech Launches Website and Call Center to Facilitate Recruitment for U.S. Phase III Study of Xilonix™ in Metastatic Colorectal Cancer

By

AUSTIN, Texas, March 12, 2015—XBiotech announced today that it has launched a website and call center to help patients with metastatic colorectal cancer learn about its U.S. Pivotal Phase III clinical trial. The Phase III study named, XilonixTM  Colorectal cancer Immunotherapy Treatment Evaluation (“XCITE”), assesses XBiotech’s True Human™ monoclonal antibody (XilonixTM) for the treatment of […]

View full entry

Tags: Colon Cancer, colorectal cancer, immunotherapy, metastatic colorectal cance, monoclonal antibody, News, Rectal Cancer, Recurrent/Relapsed Rectal Cancer, Stage IV (D)/Relapsed Colon Cancer, Stage IV Rectal Cancer, xbiotech, xcite


February 19th, 2015

Encouraging Overall Survival and Well-Being for Xilonix™ in Advanced Colorectal Cancer

By

The investigational agent Xilonix™ appears safe and effective for patients with advanced colorectal cancer. These findings were presented at the 2015 Gastrointestinal Cancers Symposium, January 15–17, in San Francisco, California.[1] According to estimates from the American Cancer Society, 93,090 cases of colon cancer and 39,610 cases of rectal cancer will be diagnosed in 2015. Colorectal […]

View full entry

Tags: advanced colorectal cancer, clinical trial, Colon Cancer, colon cancer treatment, colorectal cancer, crc, interleukin, News, Rectal Cancer, Recurrent/Relapsed Rectal Cancer, Stage IV (D)/Relapsed Colon Cancer, Stage IV Rectal Cancer


January 16th, 2015

Cyramza Added to FOLFIRI Delays Disease Progression and Extends Survival for Patients With Advanced Colorectal Cancer

By

The results of an international phase III study evaluating 1,072 patients with advanced colorectal cancer whose disease progressed on or after initial therapy will be presented at the upcoming Gastrointestinal Symposium in San Francisco. The trial results suggest that a combination of the targeted drug Cyramza™ (ramucirumab) and FOLFIRI chemotherapy provides a survival advantage over […]

View full entry

Tags: Colon Cancer, colorectal cancer, cyramza, folfiri, News, ramucirumab, Rectal Cancer, Recurrent/Relapsed Rectal Cancer, Stage IV (D)/Relapsed Colon Cancer, Stage IV Rectal Cancer


January 15th, 2015

Aggressive Chemotherapy Doubles Survival of Patients with Metastatic Colon Cancer

By

According to the results of a clinical trial presented at the 2015 Gastrointestinal Cancers Symposium in San Francisco, treatment of patients with metastatic colorectal cancer with a four-drug chemotherapy regimen plus Avastin® (bevacizumab) doubles survival when compared to a standard three drug regimen and Avastin. According to estimates from the American Cancer Society, more than […]

View full entry

Tags: avastin, bevacizumab, Colon Cancer, colorectal cancer, crc, folfiri, FOLFOX, News, Stage IV (D)/Relapsed Colon Cancer


November 3rd, 2014

FOLFOXIRI + Bevacizumab Improves Outcomes for Metastatic Colorectal Cancer

By

According to a recent report in The New England Journal of Medicine, initial treatment with FOLFOXIRI plus Avastin® (bevacizumab), rather than FOLFIRI plus Avastin, improved progression-free survival in adults with inoperable metastatic colorectal cancer. According to estimates from the American Cancer Society, more than 102,000 new cases of colon cancer and about 40,000 new cases […]

View full entry

Tags: Colon Cancer, colorectal cancer, folfiri, folfoxiri, metastatic, metastatic colorectal cancer, News, Rectal Cancer, Recurrent/Relapsed Rectal Cancer, Stage IV (D)/Relapsed Colon Cancer, Stage IV Rectal Cancer


October 23rd, 2014

Novel Agent Granted Fast Track Designation for Refractory Metastatic Colorectal Cancer

By

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to TAS-102, a novel agent currently under investigation for the treatment of refractory metastatic colorectal cancer. According to estimates from the American Cancer Society, more than 102,000 new cases of colon cancer and about 40,000 new cases of rectal cancer were diagnosed in […]

View full entry

Tags: Colon Cancer, colorectal cancer, News, Rectal Cancer, refractory colorectal cancer, Stage IV (D)/Relapsed Colon Cancer, Stage IV Rectal Cancer, TAS-102


August 26th, 2014

Doctors find that Cholesterol Lowering Statin Drugs may Improve Survival From Colon Cancer

By

According to a new U.K. study, statins, which are widely used cholesterol-lowering drugs, appear to improve colon cancer survival.  The study found that overall, colon cancer patients who took statins such as Lipitor and Zocor had a 29 percent lower risk of dying from their cancer compared to non-users.(1) According to estimates from the American Cancer […]

View full entry

Tags: Adjuvant (I-III, A-C) Colon Cancer, Colon Cancer, News, Screening/Prevention Colon Cancer, Stage IV (D)/Relapsed Colon Cancer, statins


August 20th, 2014

Exercise & Diet Rich in Fish May Help Prevent Colon Cancer’s Return

By

A new study suggests that regular exercise and a diet that includes fish may help colon cancer patients improve their odds of avoiding a cancer recurrence. (1) The likelihood that patients will suffer a return of colon cancer more than doubles if they eat fish less than twice a week, or if they get less […]

View full entry

Tags: Adjuvant (I-III, A-C) Colon Cancer, Colon Cancer, diet, News, nutrition, recurrence, Screening/Prevention Colon Cancer, Stage IV (D)/Relapsed Colon Cancer


July 9th, 2014

TAS-102 Improves Survival in Advanced Colorectal Cancer

By

Researchers recently reported that the new combination agent TAS-102 improves overall survival in patients whose metastatic colorectal cancer is refractory to standard therapies. These results were recently reported at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona.1 According to estimates from the American Cancer Society, more than 102,000 new cases of colon cancer and about […]

View full entry

Tags: Colon Cancer, colorectal cancer, crc, News, Rectal Cancer, Recurrent/Relapsed Rectal Cancer, Stage IV (D)/Relapsed Colon Cancer, Stage IV Rectal Cancer, TAS-102


June 20th, 2014

Chemotherapy Regimens paired with Avastin or Erbitux Extended Survival for Patients with Metastatic Colorectal Cancer

By

In a plenary session of the American Society of Clinical Oncology (ASCO) meeting in Chicago, researchers reported that treatment of metastatic colorectal cancer with Avastin® (bevacizumab) or Erbitux® (cetuximab) and standard chemotherapy (FOLFOX or FOLFIRI) regimens led to a new benchmark median survival time of 29 months. The results presented as ASCO were from the […]

View full entry

Tags: asco, avastin, Colon Cancer, colorectal cancer, erbitux, News, Rectal Cancer, Recurrent/Relapsed Rectal Cancer, Stage IV (D)/Relapsed Colon Cancer, Stage IV Rectal Cancer